Clinical Trial Update: A Phase I/II Study of Dasatinib and Dacarbazine [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II study evaluating dasatinib in combination with dacarbazine for metastatic melanoma has completed, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dacarbazine (DTIC-Dome) (dacarbazine)
• Sprycel (dasatinib) (dasatinib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Metastatic Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2012-06-26